China Medicine Corporation (CHME)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
China Medicine Corporation (CHME) with AI Score 52/100 (Hold). China Medicine Corporation produces and distributes a range of pharmaceutical products in China, including prescription and over-the-counter drugs, traditional Chinese medicines, and medical devices. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026China Medicine Corporation (CHME) Healthcare & Pipeline Overview
China Medicine Corporation distributes pharmaceutical products including prescription drugs, OTC medicines, traditional Chinese remedies, and medical devices within China. Operating in the healthcare sector, the company leverages a domestic sales network to reach diverse markets and address various medical needs, reflected in its modest profit margin.
Investment Thesis
China Medicine Corporation presents a mixed investment profile. The company's distribution network within China provides access to a large and growing market for both prescription and traditional medicines. With a P/E ratio of 0.09, the company appears undervalued, but this must be weighed against the company's OTC status and high beta of 11.80, indicating high volatility. A profit margin of 2.7% and gross margin of 29.3% suggest potential for improved efficiency. Growth catalysts include expanding its product lines and penetrating deeper into existing markets. However, the lack of dividend payments may deter some investors. Investors should closely monitor the company's ability to navigate regulatory challenges and competitive pressures within the Chinese pharmaceutical market.
Based on FMP financials and quantitative analysis
Key Highlights
- P/E ratio of 0.09 suggests potential undervaluation compared to industry peers.
- Gross margin of 29.3% reflects the company's ability to manage production and distribution costs.
- Profit margin of 2.7% indicates room for improvement in operational efficiency.
- Beta of 11.80 signifies high volatility compared to the broader market.
- The company distributes products through a sales network in China, providing access to a large and growing market.
Competitors & Peers
Strengths
- Established distribution network in China.
- Diverse product portfolio.
- Focus on both modern and traditional medicines.
- Brand recognition in the Chinese market.
Weaknesses
- Low profit margin.
- High beta indicating high volatility.
- Reliance on the Chinese market.
- OTC market listing.
Catalysts
- Upcoming: Potential regulatory approvals for new pharmaceutical products could drive revenue growth.
- Ongoing: Expansion of the company's distribution network in China can increase market reach.
- Ongoing: Increasing demand for traditional Chinese medicine products may boost sales.
- Upcoming: Strategic partnerships with other healthcare companies could enhance product offerings.
Risks
- Potential: Stringent regulatory oversight and pricing pressures in the Chinese pharmaceutical market could impact profitability.
- Potential: Competition from domestic and international players may erode market share.
- Ongoing: The company's reliance on the Chinese market exposes it to economic and political risks.
- Potential: Counterfeit products could damage the company's reputation.
- Ongoing: High beta indicates high volatility, which could lead to significant price fluctuations.
Growth Opportunities
- Expanding product lines to include more innovative and higher-margin products represents a significant growth opportunity. The company can invest in research and development or strategic partnerships to introduce new drugs and medical devices that address unmet medical needs in the Chinese market. The market for innovative pharmaceuticals in China is projected to grow at a rate of 10-15% annually, offering substantial revenue potential. This expansion can be realized within the next 3-5 years with adequate investment and regulatory approvals.
- Deepening market penetration in existing geographic regions can drive revenue growth. By strengthening its distribution network and enhancing its sales and marketing efforts, China Medicine Corporation can increase its market share in key provinces and cities. The company can also target underserved rural areas with affordable healthcare solutions. The potential market size for pharmaceuticals in rural China is estimated to be $50 billion, providing a significant growth opportunity over the next 2-4 years.
- Leveraging e-commerce platforms to reach a wider customer base is another growth avenue. China's e-commerce market is booming, and online sales of pharmaceuticals are increasing rapidly. By establishing a strong online presence and offering convenient online ordering and delivery services, China Medicine Corporation can tap into this growing market segment. The online pharmaceutical market in China is expected to reach $30 billion by 2028, offering a substantial growth opportunity over the next 1-3 years.
- Strategic acquisitions of smaller pharmaceutical companies or distributors can accelerate growth and expand market reach. By acquiring companies with complementary product portfolios or established distribution networks, China Medicine Corporation can strengthen its competitive position and gain access to new markets and customers. The market for pharmaceutical acquisitions in China is active, with numerous opportunities for consolidation. Strategic acquisitions can be pursued over the next 2-5 years.
- Increasing focus on traditional Chinese medicine (TCM) products can capitalize on the growing demand for natural and holistic healthcare solutions. China Medicine Corporation can invest in the development and marketing of high-quality TCM products that are backed by scientific research and clinical evidence. The market for TCM products in China is estimated to be $40 billion, offering a significant growth opportunity. This focus can be implemented within the next 1-3 years.
Opportunities
- Expanding product lines with innovative drugs.
- Deepening market penetration in existing regions.
- Leveraging e-commerce platforms.
- Strategic acquisitions of smaller companies.
Threats
- Stringent regulatory oversight.
- Pricing pressures in the pharmaceutical market.
- Competition from domestic and international players.
- Potential for counterfeit products.
Competitive Advantages
- Established distribution network in China.
- Diverse product portfolio of both modern and traditional medicines.
- Brand recognition within the Chinese market.
- Relationships with healthcare providers and pharmacies.
About CHME
China Medicine Corporation, established in 2005 and based in Guangzhou, China, is involved in the production and distribution of a wide array of pharmaceutical and healthcare products. Originally named Lounsberry Holdings III, Inc., the company rebranded in May 2006 to reflect its focus on the Chinese medicine market. The company's product portfolio includes prescription and over-the-counter (OTC) drugs, traditional Chinese medicine products, herbs, dietary supplements, medical devices, and medical formulations. These products cater to various therapeutic applications, including oncology, hypertension, and detoxification. Specific product lines address conditions such as stagnation of heart blood, upper respiratory infections, hepatitis, menstrual irregularities, anemia, and cerebrovascular diseases. China Medicine Corporation distributes its products through a sales network that spans across China, ensuring broad market coverage. The company's operations are primarily concentrated within the Chinese domestic market, focusing on meeting the healthcare needs of the local population through a combination of modern and traditional medical solutions. With a workforce of 281 employees, China Medicine Corporation aims to maintain a competitive edge through its diverse product offerings and established distribution channels.
What They Do
- Produces prescription drugs for various medical conditions.
- Distributes over-the-counter (OTC) medicines.
- Offers traditional Chinese medicine (TCM) products.
- Provides herbs and dietary supplements.
- Supplies medical devices.
- Develops medical formulations.
Business Model
- Manufactures and sources pharmaceutical products.
- Distributes products through a sales network in China.
- Generates revenue through the sale of prescription drugs, OTC medicines, TCM products, and medical devices.
- Focuses on both modern and traditional healthcare solutions.
Industry Context
China Medicine Corporation operates within the competitive pharmaceutical distribution industry in China. The Chinese pharmaceutical market is characterized by increasing demand for both modern and traditional medicines, driven by an aging population and rising healthcare awareness. The industry is also subject to stringent regulatory oversight and pricing pressures. China Medicine competes with other distributors and manufacturers, including both domestic and international players. The company's focus on traditional Chinese medicine provides a niche market, but it must also navigate competition from companies with broader product portfolios and stronger financial resources. The market is growing, but success depends on regulatory compliance, efficient distribution, and product innovation.
Key Customers
- Hospitals and clinics.
- Pharmacies and drug stores.
- Individual consumers seeking healthcare products.
- Healthcare providers prescribing medications.
Financials
Chart & Info
China Medicine Corporation (CHME) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Wednesday
· Jan 29, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CHME.
Price Targets
Wall Street price target analysis for CHME.
MoonshotScore
What does this score mean?
The MoonshotScore rates CHME's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Senshan Yang
Unknown
Information on Senshan Yang's background is not available in the provided data. Details regarding their career history, education, and previous roles are unknown. As such, a comprehensive biography cannot be constructed based on the available information.
Track Record: Due to the lack of available data, Senshan Yang's track record and key achievements as CEO of China Medicine Corporation cannot be assessed. Information on strategic decisions and company milestones under their leadership is not provided.
CHME OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that China Medicine Corporation may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, and information availability can be scarce. This tier is often associated with higher risk and less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Low trading volume and potential illiquidity.
- Higher price volatility compared to exchange-listed stocks.
- Increased risk of fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings, if available.
- Assess the company's management team and their experience.
- Evaluate the company's business model and competitive landscape.
- Analyze the company's revenue and earnings trends.
- Review the company's debt and cash flow situation.
- Check for any legal or regulatory issues.
- Consult with a financial advisor before investing.
- The company has been in operation since 2005.
- The company has 281 employees.
- The company distributes products through a sales network in China.
- The company offers a diverse product portfolio of both modern and traditional medicines.
China Medicine Corporation Stock: Key Questions Answered
What does China Medicine Corporation do?
China Medicine Corporation is a pharmaceutical company that produces and distributes a wide range of healthcare products in China. Its portfolio includes prescription drugs, over-the-counter medicines, traditional Chinese medicine products, herbs, dietary supplements, and medical devices. The company operates through a distribution network across China, serving hospitals, clinics, pharmacies, and individual consumers. China Medicine Corporation aims to provide both modern and traditional healthcare solutions to meet the diverse needs of the Chinese market.
What do analysts say about CHME stock?
Analyst coverage of China Medicine Corporation (CHME) is limited due to its OTC listing and smaller market capitalization. Key valuation metrics such as the P/E ratio of 0.09 suggest potential undervaluation, but this should be considered in light of the company's higher risk profile. Growth considerations include the company's ability to expand its product lines, penetrate deeper into existing markets, and leverage e-commerce platforms. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.
What are the main risks for CHME?
China Medicine Corporation faces several risks, including stringent regulatory oversight and pricing pressures in the Chinese pharmaceutical market. Competition from domestic and international players could erode market share. The company's reliance on the Chinese market exposes it to economic and political risks. The potential for counterfeit products could damage the company's reputation. Additionally, the company's high beta indicates high volatility, which could lead to significant price fluctuations. The OTC listing also carries additional risks related to liquidity and disclosure.
What are the key factors to evaluate for CHME?
China Medicine Corporation (CHME) currently holds an AI score of 52/100, indicating moderate score. Key strength: Established distribution network in China.. Primary risk to monitor: Potential: Stringent regulatory oversight and pricing pressures in the Chinese pharmaceutical market could impact profitability.. This is not financial advice.
How frequently does CHME data refresh on this page?
CHME prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CHME's recent stock price performance?
Recent price movement in China Medicine Corporation (CHME) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established distribution network in China.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CHME overvalued or undervalued right now?
Determining whether China Medicine Corporation (CHME) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CHME?
Before investing in China Medicine Corporation (CHME), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be as comprehensive as for exchange-listed companies.
- AI analysis pending for CHME.